Ask VialBase
Research

Effect of Semaglutide on Ovulation and Reproductive Outcomes in PCOS — VialBase Research

Trial Summary

Phase 3 trial investigating semaglutide’s ability to restore ovulatory cycles in women with PCOS. PCOS is the most common cause of anovulatory infertility, and insulin resistance/hyperinsulinemia are key drivers. GLP-1 RAs address the metabolic root cause, potentially restoring ovulation through weight loss and improved insulin sensitivity.

Design

  • Type: Randomized, double-blind, placebo-controlled, multicenter
  • Population: Women of reproductive age with PCOS and anovulation
  • Arms: Semaglutide vs. placebo
  • Duration: Treatment period with ovulation monitoring over multiple cycles
  • Key measures: Ovulation rate, menstrual cycle regularity, hormonal profiles (LH, FSH, testosterone, SHBG), metabolic parameters

Key Outcomes

Trial is currently recruiting; no results available yet.

Significance for Peptide Research

This trial represents a novel reproductive endocrinology application for GLP-1 RAs. If successful, semaglutide could become a first-line fertility-adjacent therapy for PCOS, addressing both the metabolic syndrome components and the reproductive dysfunction simultaneously. This is a strong example of the peptide therapeutic expansion beyond metabolic disease trend.

See Also